Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Xiaolan RuanJin-Hui LiangYufei PanRui CaiRong Jun ZhangZhuokai HeXi YangZhijie NiuWei JiangPublished in: Cancer (2021)
Clinical studies on vascular endothelial growth factor receptor (VEGFR)-targeted therapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) are limited. A recent preclinical study that evaluated apatinib in models of NPC showed a high objective response rate and a favorable safety profile. Our data further confirmed good efficacy in patients with lung metastasis. Further studies of the efficacy and safety of apatinib combined with immune checkpoint inhibitors or chemotherapy in NPC is warranted.
Keyphrases
- vascular endothelial growth factor
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- endothelial cells
- double blind
- open label
- cross sectional
- big data
- cancer therapy
- radiation therapy
- stem cells
- cell therapy
- case control
- drug delivery
- chemotherapy induced
- bone marrow
- placebo controlled
- smoking cessation
- deep learning